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Abstract
Background: Treatment regimens for active tuberculosis (TB) that are intermittent, or use rifampin during only the initial
phase, offer practical advantages, but their efficacy has been questioned. We conducted a systematic review of treatment
regimens for active TB, to assess the effect of duration and intermittency of rifampin use on TB treatment outcomes.
Methods and Findings: PubMed, Embase, and the Cochrane CENTRAL database for clinical trials were searched for
randomized controlled trials, published in English, French, or Spanish, between 1965 and June 2008. Selected studies
utilized standardized treatment with rifampin-containing regimens. Studies reported bacteriologically confirmed failure
and/or relapse in previously untreated patients with bacteriologically confirmed pulmonary TB. Pooled cumulative
incidences of treatment outcomes and association with risk factors were computed with stratified random effects meta-
analyses. Meta-regression was performed using a negative binomial regression model. A total of 57 trials with 312 arms and
21,472 participants were included in the analysis. Regimens utilizing rifampin only for the first 1–2 mo had significantly
higher rates of failure, relapse, and acquired drug resistance, as compared to regimens that used rifampin for 6 mo. This was
particularly evident when there was initial drug resistance to isoniazid, streptomycin, or both. On the other hand, there was
little evidence of difference in failure or relapse with daily or intermittent schedules of treatment administration, although
there was insufficient published evidence of the efficacy of twice-weekly rifampin administration throughout therapy.
Conclusions: TB treatment outcomes were significantly worse with shorter duration of rifampin, or with initial drug
resistance to isoniazid and/or streptomycin. Treatment outcomes were similar with all intermittent schedules evaluated, but
there is insufficient evidence to support administration of treatment twice weekly throughout therapy.
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When rifampin was first introduced, it held the promise of
exceptional potency as an agent for treatment of Mycobacterium
tuberculosis (the cause of tuberculosis [TB]). A series of randomized
trials, most conducted 20–35 y ago, established that rifampin-
containing regimens could achieve high cure rates with as few as
6 mo of therapy, even when given intermittently [1]. These trials
ushered in the modern era of short-course chemotherapy and
established the scientific rationale for the standardized regimens
currently recommended by the World Health Organization
(WHO) [2]. WHO recommends direct observation of all doses
of rifampin to prevent rifampin resistance, which is associated with
much worse treatment outcomes, especially when combined with
isoniazid resistance as multi-drug resistance (MDR) [3,4]. This
direct observation is facilitated by shorter duration of rifampin,
and/or by intermittent dosing schedules.
However, the frequency of all forms of drug resistance has
steadily increased in many countries over the last 20 y [5–7]. The
effectiveness of current empiric regimens in treating patients with
unrecognized initial drug resistance of any form, including
isoniazid mono-resistance, is unclear since this was not a focus
of earlier trials. In particular, the adequacy of regimens that use
rifampin only in the initial phase, or are intermittent throughout,
may be questionable in settings with increasing drug resistance. In
addition, the individual trials that form the scientific basis for
current therapy were mostly small trials with limited power to
evaluate the duration and intermittency of rifampin use. Hence
meta-analysis of these trials can allow evaluation of factors that
may have a small but clinically relevant effect on treatment
outcomes.
In light of these uncertainties, we have conducted a systematic
review of treatment regimens for active TB, to provide a basis for
recommendations for revised treatment guidelines.
Review Questions
Our systematic review aimed to address two specific questions:
1. What are the rates of treatment failure, relapse, and acquired
drug resistance if rifampin is given only in the initial intensive
phase (the first 1–2 mo), compared to longer duration?
2. What are the rates of treatment failure, relapse, and acquired
drug resistance with different dose administration schedules of
therapy?
Methods
Search Strategy
We searched three electronic databases—PubMed, Embase,
and the Cochrane CENTRAL database—for studies of treatment
of active TB (i.e., disease). The search was restricted to
randomized controlled trials published in English, French, and
Spanish from 1965 up to June 2008. Our keywords included
tuberculosis or TB, treatment or therapy, failure or relapse, or
drug resistance. To identify additional relevant articles, we
searched reference lists of identified original articles, recent
systematic reviews [8–11], a review of all the British Medical
Research Council trials [12], recent treatment guidelines [13,14],
and texts [15,16].
Study Selection
We included original reports of randomized controlled trials
that reported treatment outcomes of bacteriologically confirmed
failure and/or relapse. In selected trials, all patients had active
pulmonary TB that was bacteriologically confirmed by AFB smear
microscopy and/or mycobacterial culture, and had not been
previously treated (i.e., were new cases). Treatment was standard-
ized and included at least isoniazid and rifampin. We excluded
trials or arms that included rifapentine or rifabutin therapy or non-
drug therapy (e.g., immunotherapeutic vaccines). We also
excluded trials, or arms, that involved once-weekly or mono-drug
therapy, as these are now considered inadequate [13,14].
The selection of articles for review was done independently by
two investigators in three stages: titles alone, followed by abstracts,
and then full text articles. Decisions were compared and
disagreements about study selection were resolved by consensus
or by involving a third reviewer.
Data Extraction and Quality Assessment
We reviewed all selected studies using standardized forms to
extract data about patient population and characteristics,
treatment regimens, pretreatment drug-susceptibility testing,
supervision of treatment, funding source, and number of patients
who started treatment, defaulted or were otherwise lost, died,
failed, or relapsed. Two reviewers extracted the data, with
disagreements resolved by consensus.
We restricted the studies reviewed to randomized trials with
bacteriologic confirmation of initial diagnosis, failure, and/or
relapse—considered high-quality methods. Included studies were
considered of high quality if less than 10% of patients refused
therapy, dropped out, moved away, or were otherwise unaccounted
for during therapy. In addition, randomized trials were considered
high quality if they used an allocation concealment approach such
as central randomization, numbered opaque sealed envelopes,
sealed envelopes from a closed bag, numbered or coded bottles or
containers, or if treatments were assigned by a central pharmacy.
Outcomes
In line with internationally accepted definitions [17], treatment
failure was defined as sputum smears and/or cultures that were
consistently positive or requiring treatment at the end of therapy (if
less than 5 mo) or after at least 5 mo of therapy. Relapse was
defined as recurrence of positive smears and/or cultures that
required therapy after completion of treatment with apparent
cure. Initial drug resistance was defined as pretreatment resistance
in patients without a history of previous treatment, and
categorized as pan-sensitive, isoniazid resistant, streptomycin
resistant, or resistant to both—termed poly-drug resistance.
Patients with initial rifampin resistance, including MDR, were
excluded from analysis, if identified in the published report.
Acquired drug resistance was defined as new or additional
resistance to one or more of the TB drugs received, among
failures or relapses.
Data Synthesis and Analysis
We were interested in understanding the efficacy of different
regimens in preventing failure, relapse, and acquired drug
resistance—end-points with objective microbiological definitions
that were consistent across trials. Therefore, we used a per-
protocol analysis, excluding patients who did not complete therapy
because they developed serious adverse reactions, died, defaulted,
dropped out, or were otherwise not accounted for.
We restricted our first analysis to those trials within which
regimens differed by the duration of rifampin, or dosing schedule
(intermittency), but were otherwise comparable. To increase the
number of trials with head-to-head comparisons analyzed,
regimens were considered comparable even if they differed by
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comparisons, we calculated cumulative incidence of failure,
relapse, and acquired drug resistance, and the Mantel-Haenszel
pooled difference in cumulative incidence and 95% confidence
interval (CI) for each comparison [18]. One advantage of this
method is that 0-cell corrections are not necessary to calculate the
MH pooled risk difference [18]. We assessed heterogeneity of risk
differences for each comparison, by estimating the I
2 statistic and
associated 95% CIs [19]. For this calculation, studies in which
both arms had no events were corrected by 0.5.
Because few trials with head-to-head comparisons were
identified, in our second analysis we pooled results across all
trials, effectively treating each arm within each trial as an
independent cohort. For the across-trial analysis, we used a
random effects meta-analysis to estimate the overall pooled
estimates of cumulative incidence and 95% CI of failure, relapse,
and acquired drug resistance using Proc Nlmixed in SAS (SAS
Institute, Carey, NC, USA) [20]. We used the exact binomial
likelihood approach [20], which uses a binomial distribution to
approximate the distribution of the outcome of interest. This
approach accounts for study size and includes a random effect to
account for between-study heterogeneity. When proportions are
the outcome measure, this approach has been demonstrated to
produce less-biased estimates of the pooled effect and the
Figure 1. Summary of literature search and study selection.
doi:10.1371/journal.pmed.1000146.g001
Standardized TB Treatment and Outcomes
PLoS Medicine | www.plosmedicine.org 3 September 2009 | Volume 6 | Issue 9 | e1000146between-study variability [20]. We assessed heterogeneity of
proportions of participants with outcomes of interest, within
subgroups defined by covariates of interest by estimating the I
2
statistic and associated 95% CIs [19]. To calculate I
2,0 - c e l l sw e r e
corrected by 0.5.
To minimize heterogeneity, we performed subgroup analyses
stratified by predefined covariates of interest. These included
duration and dosing schedule of rifampin, initial drug resistance,
use of pyrazinamide or streptomycin, and number of drugs to
which the organism was susceptible used in the initial or
continuation phase (the initial intensive phase was defined as
the initial period when more drugs were used—usually the first 1–
2 mo—while the continuation phase was the remainder of
therapy). We also examined the effect of supervision of therapy
(i.e. directly observed therapy [DOT]), proportion that were
smear positive, and default or other losses during treatment phase
follow-up.
Finally, meta-regression was used to estimate the effect of the
treatment factors of interest, after adjustment for other
potentially confounding patient and treatment covariates.
Because the outcomes we were pooling were proportions rather
than odds ratios, and because these proportions were usually
small, we performed meta-regression using the Poisson model
[21] that allowed for overdispersion (i.e., negative binomial
Table 1. Summary of studies reviewed (all randomized
controlled trials with rifampin-containing regimens in new
cases).
Characteristic By Study By Arm
N % N %
Language of publication
English 54 95 299 96
French 3 5 14 4
Year when study began
1969–1979 26 45 178 56
1980–1989 16 28 104 33
1990–1999 13 24 26 9
2000–Present 2 3 5 2
Sponsorship
Public 56 98 311 99
Corporate 1 2 2 1
Measured failure
Yes 56 98 311 99
No 1 2 2 1
Measured relapse
Yes 53 93 302 97
No 4 7 11 3
Measured acquired drug resistance
Yes 39 69 264 84
No 18 31 49 16
Quality in treatment
High (#10% dropout/lost) 29 51 182 58
Poor (.10% dropout/lost) 28 49 131 42
Quality in follow-up
High (#10% lost) 40 67 217 72
Poor (.10% lost) 17 33 85 28
Quality of randomization
Adequate 39 70 181 58
Not stated or inadequate 18 30 132 42
Blinding
Single or double 4 7 14 4
None 53 93 299 96
Supervision of rifampin
None/partial 27 47 49 16
All doses 30 53 264 84
Isoniazid
Not used 0 0 1 1
Used 57 100 312 99
Pyrazinamide
Not used 11 19 61 19
Used 46 81 252 81
Streptomycin
Not used 28 49 101 32
Used 29 51 212 68
Use of second line drugs
None 55 99 312 99
Yes – (1 drug) 2 1 2 1
Parameters Varied Within Studies – Summary by
Arm Only N %
Number of drugs used to which strains sensitive
Initial intensive phase
12 1
26 8 2 3
3 153 52
4 or more 71 24
Continuation phase
0o r1 7 0 2 4
2 144 50
3 or more 74 26
Drug sensitivity
Unknown (Mix) 19 6
Pan-sensitive 128 41
INH resistance 68 22
Streptomycin 54 17
Poly-drug resistance 44 14
Rifampin use and duration
1–2 mo 72 23
3–4 mo 42 13
5–7 mo 178 57
8+ mo 21 7
Schedule of administration
Daily throughout 161 51
Daily then thrice weekly 35 11
Daily then twice weekly 45 15
Thrice weekly throughout 70 22
Twice weekly throughout 2 1
doi:10.1371/journal.pmed.1000146.t001
Table 1. Cont.
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comparable regimens: Failure.
Ref Regimens
a Fail Non Fail Non Risk Difference
2 versus 3–4 mo 2m o 3 – 4m o
[84,110] 2SHRZ/2HZ 1 123 1 248 0.4%
2SHRZ/2HR
[76,93] 2SHRZ 0 84 0 81 0
3SHRZ
Pooled risk difference (95% CI) 0.3% (0.9% to 1.4%)
Overall I
2 (95% CI) 0( 2 , 2)
2 versus 6 mo 2m o 6m o
[43,111] 2SHRZ/4HZ 3 206 0 212 1.4%
SHRZ/4HR
[26] 2EHRZ/6HE 41 771 12 371 1.8%
2EHRZ/4HR
[112] 2HRZE/4[HRZ]2 3 41 3 51 1.3%
2HRZE/4[HZE]2
Pooled risk difference (95% CI) 1.7% (0% to 3.4%)
Overall I
2 (95% CI) 0 (0 to 0.73)
4 versus 6 mo 4m o 6m o
[37–39] 2SHRZ/2HR 0 91 1 89 21.1%
2SHRZ/4HR
[37–39] 2SHRZ/2HRZ 0 91 0 89 0%
2SHRZ/4HRZ
[63] 2SHRZ/2HR/4H 4 564 1 518 0.5%
2SHRZ/4HR
[87] 2HRZ/2HR 0 59 1 53 22.0%
2HRZ/4[HR]3
[90] 2HRZE/2HR 0 33 3 64 24.5%
2HRZE/4HR
[91] 2SHRZ/2HR 0 79 0 83 0%
2SHRZ/4HR
[91] 2SHRZ/2HRZ 0 83 0 87 0%
2SHRZ/4HRZ
Pooled risk difference (95% CI) 20.1% (20.7% to 0.4%)
Overall I
2 (95% CI) 0.10 (0 to 0.7)
6 versus 9+ mo 6m o 9 + mo
[48] 6[SHRZ]3 16 7 4 5 0 25.9%
8[SHRZ]3
[72] 2HRZE/4[HR]2 5 129 4 131 0.8%
2HRZE/10[HR]2
[85] 2HRZE/4HR 1 41 0 37 2.4%
2HRZE/7HR
[54,55] 2EHR/4HR 1 116 0 282 0.9%
2EHR/7,10,16HR
[54,55] 2SHR/4HR 0 74 0 213 0%
2SHR/7,10,16HR
Pooled risk difference (95% CI) 20.2% (21.9% to 1.5%)
Overall I
2 (95% CI) 0 (0 to 0.75)
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the unit of analysis, cumulative incidence of TB treatment
outcomes was the dependent variable, and TB treatment
characteristics were the independent variables. An offset was
used to account for size of study. In this approach, residual
heterogeneity between studies is accounted for in the dispersion
parameter. As such we interpreted the dispersion parameter as
indicating there was no remaining unexplained heterogeneity if
the value was not significantly different from zero and as
minimal heterogeneity if the value was less than 1.0 [22]. Effect
estimates of the meta-regression model were interpreted as
adjusted incidence rate ratios (IRR) [21]. We tested the
significance of each factor in the models using the likelihood
ratio test. Two models were used. The first included rifampin
duration, intermittent schedule, use of pyrazinamide and
streptomycin, number of drugs in initial or continuation phases
to which organisms were susceptible, length of follow-up after
end of treatment (for relapse and acquired drug resistance),
directly observed therapy (DOT), and non-completion of
therapy because of protocol violations, patient refusal, default,
moved, or lost. The second model included initial drug resistance
with all the same factors, except the number of sensitive drugs in
initial or continuation phases—which could not be included
because of substantial co-linearity between these factors and
drug resistance.
Results
Description of Included Trials
As seen in Figure 1, 2,215 citations were identified from the
search of the three electronic databases. Of these, 237 were
retained for abstract review and 166 for full text review. An
additional 135 full texts were identified from the search of the
references of the original articles and other sources. After full text
review, 75 papers describing 57 randomized trials were selected
for this analysis. These trials, summarized in Appendix Table 1 in
Text S1 [23–94], included a total of 21,472 participants in 312
different treatment arms. Of these, 612 patients died and 2,775
dropped out, were lost, or were otherwise not accounted for. This
left 18,701 analyzable participants in all trials. Failure was
analyzed for 18,085 participants in 56 studies; relapse was
reported for 15,558 participants in 53 trials, while acquired drug
resistance was reported for 11,400 participants in 39 trials
(Table 1). All trials involved adults, and in 42 all patients were
smear positive, although cultures were used to define study end-
points in all but three trials [26,90,94]. Only four trials included
HIV-infected persons, with a total of 522 HIV-infected
participants. Rifampin dose was not stated in two trials [62,94],
was 450 mg/d in three trials with a total of 618 patients
[76,89,95], and was 600 mg/d (or 10–12 mg/kg) in all the
remaining studies. In 30 trials (52%) all treatment doses were
supervised, and in 29 (51%) less than 10% refused, defaulted, or
were lost during treatment. Randomization was described in 41
trials, and was adequate in 40, but not described in 16 trials.
Median post-treatment follow-up was 24 mo (interquartile range:
18–30).
Results of Head-to-Head Comparisons
As seen in Table 2, in the studies with head-to-head
comparisons, rates of failure (Table 2) were significantly higher
in patients who received only 1–2 mo of rifampin than in patients
who received longer durations of rifampin. Rates of relapse
(Table 3) were progressively lower with longer duration of
rifampin up to 8 mo or more. In the only trial which compared
four different durations of rifampin (6 versus 9, 12, and 18 mo), all
outcomes were the same with the three longer regimens [54,86].
Acquired drug resistance (Table 4) was not associated with shorter
duration of rifampin, but this outcome was uncommon and
reported in fewer trials—limiting power. All five of the studies with
head-to-head comparisons of intermittent schedules compared
different regimens and schedules, so results could not be pooled
(Table 5).
Pooled Results across Trials
When results were pooled across all 57 trials, rifampin was given
for 1 mo in 12 arms, 2 mo in 60, 5 mo in 6, 6 mo in 170, and
7 mo in 2. Regimens with 1–2 mo of rifampin had higher failure
(Table 6) and relapse (Table 7) rates than regimens with longer
duration rifampin. Relapse rates were progressively lower with
longer rifampin duration, up to 8 mo or more of rifampin (see
Figure S1).
With regard to the different intermittent schedules compared,
evidence regarding therapy given twice weekly throughout was
limited to a single study of 223 patients who received 12 mo of
isoniazid and rifampin—daily or twice weekly [23,27]. Rates of
failure, relapse, and acquired drug resistance were less than 1%.
Because this was a single study, these results could not be pooled
and are not considered further in stratified or multivariate
analyses. The other schedules, of daily, daily then thrice weekly,
daily then twice weekly, and thrice weekly throughout, were
evaluated in numerous studies. As seen in Tables 6–8, there were
no significant differences in outcomes between these four different
treatment schedules.
Of the other factors considered, initial drug resistance was
associated with increased risk of failure, relapse, and acquired drug
resistance. In the presence of initial isoniazid or isoniazid and
streptomycin resistance (poly-drug resistance ), regimens using 1–
2 mo of rifampin had failure rates of 6.5% (95% CI: 0.7%–12.3%)
or 29% (10%–53%), respectively, in comparison with 0.2% (0%–
0.5%) in pan-sensitive TB, and relapse rates of 38% (29%–46%) or
27% (10%–44%), respectively, compared to 8.2% (4.5%–11.9%)
in pan-sensitive TB. Acquired drug resistance was also increased if
there was initial drug resistance, but this effect appeared similar
with all durations of rifampin. Interestingly, failure and acquired
drug resistance were progressively lower with use of more drugs to
which the organisms were sensitive in the initial phase (up to four
drugs), and also associated (but less strongly) with the number of
Seventeen head-to-head comparisons of rifampin duration. For one study [54,55], results with 9-, 12-, and 18-mo regimens were the same so they were combined.
aRegimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.
Letters to left of ‘‘/’’ indicate regimen in initial intensive phase; letters to right of ‘‘/’’ indicate regimen in continuation phase. First number signifies the months of initial
phase of treatment and the second number signifies the months of continuation phase treatment. [ ] indicates intermittent therapy; subscript number after [ ] indicates
number of doses per week.
doi:10.1371/journal.pmed.1000146.t002
Table 2. Cont.
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Ref Regimens
a Relapse Non Relapse Non Risk Difference
2 versus 3–4 mo 2m o 3 – 4m o
[84,110] 2SHRZ/2HZ 38 78 30 200 19.7%
2SHRZ/2HRZ
[76] 2SHRZ 20 64 8 73 13.9%
3SHRZ
Pooled risk difference (95% CI) 17.7% (10.3% to 25%
Overall I
2 (95% CI) 0( 2 , 2)
2 versus 6 mo 2m o 6m o
[43,113] 2SHRZ/4HZ 13 168 6 171 3.8%
2SHRZ/4HR
[26] 2EHRZ/6HE 57 344 6 236 11.7%
2EHRZ/4HR
[112] 2HRZE/4[HRZ]2 20 21 6 45 37%
2HRZE/4[HZE]2
Pooled risk difference (95% CI) 11.2% (8.1% to 14.3%)
Overall I
2 (95% CI) 0.88 (0.66 to 0.96)
4 versus 6 mo 4m o 6m o
[37–39] 2SHRZ/2HR 7 80 2 83 5.7%
2SHRZ/4HR
[37–39] 2SHRZ/2HRZ 10 79 0 82 11.2%
2SHRZ/4HRZ
[63] 2SHRZ/2HR/4H 38 526 23 495 2.3%
2SHRZ/4HR
[87] 2HRZ/2HR 0 57 0 52 0%
2HRZ/4[HR]3
[90] 2HRZE/2HR 3 30 6 58 20.3%
2HRZE/4HR
[91] 2SHRZ/2HR 4 70 1 79 4.2%
2SHRZ/4HR
[91] 2SHRZ/2HRZ 8 72 0 84 10.0%
2SHRZ/4HRZ
Pooled risk difference (95% CI) 6.9% (3.7% to 10.0%)
Overall I
2 (95% CI) 0.59 (0.05 to 0.82)
6 vs. 9+ mo 6m o 9 + mo
[48] 6[SHRZ]3 12 44 2 40 17%
8[SHRZ]3
[72] 2HRZE/4[HR]2 9 59 1 53 11.4%
2HRZE/10[HR]2
[74] 2HRZ/4HR 10 375 6 225 0%
2HRZ/7HR
[85] 2HRZE/4HR 1 16 1 14 20.8%
2HRZE/7HR
[54,55] 2EHR/4HR 6 96 0 213 5.9%
2EHR/7,10,16HR
[54,55] 2SHR/4HR 2 52 2 160 2.5%
2SHR/7,10,16HR
Pooled risk difference (95% CI) 4.0% (1.8% to 6.2%)
Overall I
2 (95% CI) 0.65 (0.18 to 0.86)
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aRegimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.
Letters to left of ‘‘/’’ indicate regimen in initial intensive phase; letters to right of ‘‘/’’ indicate regimen in continuation phase. First number signifies the months of initial
phase of treatment and the second number signifies the months of continuation phase treatment. [ ] indicates intermittent therapy; subscript number after [ ] indicates
number of doses per week.
doi:10.1371/journal.pmed.1000146.t003
Table 3. Cont.
Table 4. Pooled risk differences from direct head-to-head comparisons of rifampin duration or intermittent schedules in otherwise
comparable regimens: Acquired drug resistance.
Ref Regimens
a ADR Non ADR Non Risk Difference
2 versus 4 mo 2m o 4m o
[76] 2SHRZ 0 84 0 81 0
3SHRZ
Pooled risk difference (95% CI) 0%
Overall I
2 (95% CI) 0( –,– )
2 versus 6 mo 2m o 6m o
[43,114] 2SHRZ/4HZ 3 206 2 210 0.5%
2SHRZ/4HR
Pooled risk difference (95% CI) 0.5% (21.5% to 2.5%)
Overall I
2 (95% CI) 0( –,– )
4 versus 6 mo 4m o 6m o
[37–39] 2SHRZ/2HR 1 90 1 89 0%
2SHRZ/4HR
[37–39] 2SHRZ/2HRZ 0 91 0 89 0%
2SHRZ/4HRZ
[63] 2SHRZ/2HR/4HR 5 563 1 518 0.7%
2SHRZ/4HR
[91] 2SHRZ/2HR 0 79 0 83 0%
2SHRZ/4HR
[91] 2SHRZ/2HRZ 0 83 0 87 0%
2SHRZ/4HRZ
Pooled risk difference (95% CI) 0.4% (20.2% to 1.0%)
Overall I
2 (95% CI) 0 (0 to 0.74)
6 versus 9 mo 6m o 9m o
[48] 6[SHRZ]3 26 6 4 5 0 24.5%
8[SHRZ]3
[85] 2HRZE/4HR 2 40 2 35 20.6%
2HRZE/7HR
[54,55] 2EHR/4HR 0 117 0 282 0%
2EHR/7,10,16HR
[54,55] 2SHR/4HR 0 74 0 213 0%
2SHR/7,10,16HR
Pooled risk difference (95% CI) 20.8% (22.4% to 0.9%)
Overall I
2 (95% CI) 0 (0 to 0.77)
Eleven head-to-head comparisons of rifampin duration. For one study [54,55]—results with 9-, 12-, and 18-mo regimens were the same—so they were combined.
aRegimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.
Letters to left of ‘‘/’’ indicate regimen in initial intensive phase; letters to right of ‘‘/’’ indicate regimen in continuation phase. First number signifies the months of initial
phase of treatment and the second number signifies the months of continuation phase treatment. [ ] indicates intermittent therapy; subscript number after [ ] indicates
number of doses per week.
doi:10.1371/journal.pmed.1000146.t004
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phase.
Meta-Regression
When adjusted for potentially confounding treatment factors in
multivariate regression, regimens with 1–2 mo of rifampin were
associated with significantly higher failure, relapse, and acquired
drug resistance rates than the reference group of 6 mo of rifampin
(Table 9). Interestingly, adjusted relapse rates were lower with
regimens using rifampin for at least 8 mo than with the 6-mo
rifampin reference group. None of the intermittent schedules was
significantly associated with failure or relapse, although acquired
drug resistance was increased with two of the three intermittent
regimens. Streptomycin use was protective against failure, relapse,
and acquired drug resistance, while pyrazinamide use was
protective only for relapse.
The proportion smear positive, proportion HIV infected, and
duration of post-treatment follow-up were not associated with
treatment outcomes and were not included in final regression
models. Poor completion of treatment was associated with failure
or relapse, whereas supervision of therapy was not; both factors
were included in final multivariate models, although estimates are
not shown. Dispersion estimates for all three final models were less
than 1, suggesting that the treatment factors included in these
models accounted for the majority of the heterogeneity in
outcomes seen.
Discussion
In this review of 57 trials with rifampin-containing regimens,
use of rifampin only initially rather than throughout treatment
was associated with worse treatment outcomes (higher rates of
failure, relapse, and acquired drug resistance). Thrice-weekly
intermittent dosing schedules during the initial treatment phase
were associated with increased adjusted risk of acquired drug
resistance, but not relapse or failure. Initial drug resistance was
strongly associated with increased risk of poor treatment
outcomes, particularly if rifampin was used only in the initial
intensive phase. These findings have important implications for
TB treatment.
The most important finding of this review is that all three
treatment outcomes were significantly worse with regimens that
used rifampin for the first 1–2 mo rather than throughout therapy.
This finding adds considerable weight to similar findings by
Jindani and colleagues, who compared regimens containing 2 mo
versus 6 mo of rifampin [26]. This review includes many more
studies with a variety of regimens, making these results more
robust and generalizable. In this review, the failure and relapse
rates progressively declined with long duration of rifampin; such a
dose–response relationship strengthens the conclusions that a
longer duration of rifampin treatment is responsible for better
outcomes. Finally, this review included studies where drug
sensitivity testing was performed, which permitted us to detect
an increased risk of acquired drug resistance with shorter rifampin
duration and also permitted stratified analysis by underlying drug
resistance, which proved to be a very important determinant of
treatment outcomes. According to the most recent information
from WHO [96], the 8-mo regimen was the recommended initial
therapy in 24 high-incidence countries. Based on the pooled risk
differences from within trial analyses, we estimate that treatment
of 100 patients with the regimen of 2HRZE/6HE (the ‘‘8-mo’’
regimen) would result in 13 more failures and relapses than if they
received 2HRZE/4HR (the ‘‘6-mo’’ regimen). As a result,
forthcoming recommendations by WHO will recommend only
the 6-mo (rifampin throughout) regimen, and the 8-mo regimen
will no longer be recommended [97]. Results of this review suggest
that the public health benefits of switching from the 8-mo to the 6-
mo regimen should be very considerable.
The lower risk of relapse with regimens using rifampin for at
least 8 mo is consistent with subgroup analyses of other trials [98]
and a recent cohort report from Hong Kong [99]. These have
shown that patients with extensive cavitary pulmonary disease
Table 5. Pooled risk differences from direct head-to-head comparisons of rifampin duration or intermittent schedules otherwise
comparable regimens.
Reference Drug Resistance Patterns Treatment Regimens
a Treated (N) Failed (N) Relapsed (N)
b ADR (N)
b
[115,116] Pan-sensitive 2HRE/4[HR]2 93 0 16 0
2HRE/4[HRE]2 96 0 6 0
6HRE 98 0 12 0
[28,40,41] Pan-sensitive, STREP, INH, PDR 6HRZE 199 0 6 0
6[HRZE]3 199 1 8 0
[26] Pan-sensitive plus all forms of resistance except MDR 2EHRZ/6HE 402 18 1 n/a
2[EHRZ]3/6HE 410 22 1 n/a
[87] Pan-sensitive 2HRZ/2HR 158 0 0 n/a
2HRZ/2[HR]3 102 0 1 n/a
[117] Pan-sensitive plus all forms of resistance except MDR 3[HRZE]5/3.5[HR]5 39 0 n/a n/a
6.5HRZ (with FDC) 67 0 n/a n/a
Treatment outcomes are from five studies with direct head-to head-comparisons of intermittency schedules (and otherwise comparable regimens). Meta-analysis not
done, as no schedules were the same.
aRegimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.
Letters to left of ‘‘/’’ indicate regimen in initial intensive phase; letters to right of ‘‘/’’ indicate regimen in continuation phase. First number signifies the months of initial
phase of treatment and the second number signifies the months of continuation phase treatment. [ ] indicate intermittent therapy; subscript number after [ ] indicates
number of doses per week.
an/a, not available, meaning relapse and/or acquired drug resistance (ADR) not measured.
INH, isoniazid resistant; STREP, streptomycin resistant; PDR, poly-drug resistant (streptomycin+isoniazid resistant); FDC, fixed drug combinations.
doi:10.1371/journal.pmed.1000146.t005
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together these findings support recommendations to extend
therapy for patients at high risk of relapse [13]. However,
accurate identification of high-risk patients is imprecise, and
provision of extended therapy may be challenging in high-burden
settings.
The lack of effect of intermittency is interesting but has several
caveats. The timing of intermittent dosing may be quite important,
as suggested by the finding of increased risk of acquired resistance
associated with thrice-weekly therapy throughout. A cohort study
from New York City reported that patients with HIV–TB
coinfection had an increased risk of acquired rifamycin resistance
Table 6. Stratified estimates of treatment failures in RCT in new cases.
Factor Studies (N) Events/Participants (N)
Pooled Event Rate
(Across All Trials) 95% CI I
2 (95% CI)
Duration of rifampin
Rifampin 1–2 mo 72 94/4,133 1.8 0.2 to 3.3 0.36 (0.15 to 0.52)
Rifampin 3–5 mo 42 16/2,508 0.3 0 to 0.6 0 (0 to 0.35)
Rifampin 6–7 mo 178 150/10,060 0.4 0.1 to 0.7 0 (0 to 0.19)
Rifampin 8+ mo 18 10/1,384 0.2 0 to 0.6 0 (0 to 0.49)
Use of intermittent therapy
Daily throughout 159 179/11,510 0.4 0.2 to 0.7 0.07 (0 to 0.24)
Daily then thrice weekly 35 4/961 0.3 0 to 1.0 0 (0 to 0.38)
Daily then twice weekly 46 49/2,749 1.2 0.1 to 2.4 0.21 (0 to 0.45)
Thrice weekly throughout
a 70 38/2,865 0.5 0 to 1.0 0 (0 to 0.28)
Initial drug resistance
DST not done/reported 19 78/2,105 2.2 0 to 4.4 0 (0 to 0.48)
Sensitive to all TB drugs 126 120/14,900 0.3 0.1 to 0.4 0 (0 to 0.21)
Isoniazid resistance 67 25/477 2.8 0.7 to 5.0 0 (0 to 0.29)
Streptomycin resistance 54 6/316 1.3 0 to 2.7 0 (0 to 0.31)
INH+streptomycin resistant (PDR) 44 41/287 8.3 1.9 to 14.7 0 (0 to 0.34)
Duration of pyrazinamide
No pyrazinamide 59 97/4,831 0.3 0 to 0.6 0.30 (0.03 to 0.49)
1–3 mo 139 124/8,287 0.6 0.2 to 1.0 0 (0 to 0.21)
4+ mo 112 49/4,967 0.5 0.1 to 0.8 0 (0 to 0.23)
Duration of streptomycin
No streptomycin 100 188/7,907 0.6 0.2 to 0.9 0.18 (0 to 0.36)
1–3 mo 117 44/6,328 0.4 0.1 to 0.6 0 (0 to 0.23)
4+ mo 93 38/3,850 0.5 0 to 0.9 0 (0 to 0.25)
Number of drugs to which strains susceptible
b
Initial phase
0–1 drugs 2 10/29 33.2 0 to 103.5 0 (–, –)
2 drugs 66 114/1,782 2.8 0.2 to 5.2 0.52 (0.36 to 0.63)
3 drugs 151 43/5,664 0.3 0 to 0.5 0 (0 to 0.20)
4 drugs 72 25/8,505 0.1 0 to 0.1 0 (0 to 0.28)
Continuation phase
0–1 drugs 69 54/588 2.6 0 to 6.1 0 (0 to 0.28)
2 drugs 142 113/9,838 0.2 0.1 to 0.4 0 (0 to 0.20)
3 or more drugs 74 25/5,528 0.1 0 to 0.2 0 (0 to 0.27)
Supervision of therapy
All doses fully supervised 232 145/10,446 0.4 0.1 to 0.7 0 (0 to 0.16)
None or partial DOT 78 125/7,639 0.4 0.1 to 0.7 0.19 (0 to 0.39)
Completion of therapy
Good (#10% dropouts) 181 102/11,837 0.3 0.1 to 0.5 0 (0 to 0.19)
Poor (.10% dropouts) 129 168/6,248 0.9 0.3 to 1.5 0.25 (0.07 to 0.40)
Event rate and 95% CI are in bold if confidence intervals for two or more strata do not overlap.
aIn all but one trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.
bIn a few trials, the number of drugs was the same throughout—these were classified according to the starting regimen.
doi:10.1371/journal.pmed.1000146.t006
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intensive phase but not if they were treated with intermittent
dosing only during the continuation phase [100].
Te other important finding is the previously underestimated
impact of primary isoniazid resistance on failure, relapse, and
acquired resistance. This important effect is a powerful argument
for widespread availability of rapid, inexpensive testing for
resistance to isoniazid (as well as for rifampin), or for regimens
that do not require optimal activity from isoniazid. The influence
of primary streptomycin resistance is likely to be less important,
Table 7. Stratified estimates of relapse in RCT in new cases.
Factor Studies (N) Events/Participants (N)
Pooled Event Rate
(Across All Trials) 95% CI I
2 (95% CI)
Overall
Duration of rifampin
Rifampin 1–2 mo 70 367/3,349 16.0 11.1 to 20.9 0.67 (0.58 to 0.74)
Rifampin 3–5 mo 42 185/2,389 7.1 4.5 to 9.7 0.65 (0.52 to 0.75)
Rifampin 6–7 mo 171 364/8,639 3.8 2.9 to 4.7 0 (0 to 0.19)
Rifampin 8+ mo 18 14/1,181 1.0 0.2 to 1.7 0 (0 to 0.46)
Use of intermittent therapy
Daily throughout 153 566/9,829 4.8 3.6 to 6.0 0.56 (0.49 to 0.64)
Daily then thrice weekly 34 33/907 2.9 0.7 to 5.2 0 (0 to 0.38)
Daily then twice weekly 44 181/2,367 7.3 4.0 to 10.7 0.6 (0.45 to 0.71)
Thrice weekly throughout
a 70 150/2,455 5.7 3.1 to 8.3 0.23 (0 to 0.43)
Initial drug resistance
DST not done/reported 17 124/1,337 7.8 3.0 to 12.5 0.82 (0.73 to 0.88)
Sensitive to all TB drugs 123 684/13,302 3.7 2.8 to 4.7 0.66 (0.59 to 0.72)
Isoniazid resistance 65 60/403 11.4 6.5 to 16.2 0 (0 to 0.28)
Streptomycin resistance 54 36/299 9.7 4.6 to 14.9 0 (0 to 0.32)
INH+streptomycin resistant (PDR) 42 26/217 10.1 4.2 to 15.9 0 to (0 to 0.34)
Duration of pyrazinamide
No pyrazinamide 56 197/3,532 5.1 2.8 to 7.4 0.67 (0.58 to 0.75)
1–3 mo 136 445/7,539 4.9 3.5 to 6.4 0.46 (0.34 to 0.56)
4+ mo 109 288/4,487 6.1 3.9 to 8.2 0.38 (0.22 to 0.51)
Duration of streptomycin
No streptomycin 95 286/6,277 2.7 1.8 to 3.6 0.44 (0.29 to 0.56)
1–3 mo 115 441/5,680 7.5 5.5 to 9.6 0.65 (0.61 to 0.73)
4+ mo 91 203/3,601 5.6 3.4 to 7.7 0.27 (0.06 to 0.44)
Number of drugs to which strains susceptible
b
Initial phase
0–1 drugs 2 2/17 9.3 0.0 to 30.2 0 (–, –)
2 drugs 63 72/1,210 6.6 2.7 to 10.4 0.06 (0 to 0.31)
3 drugs 148 284/5,191 4.1 2.6 to 5.6 0.36 (0.22 to 0.47)
4 drugs 71 448/7,803 4.1 2.4 to 5.8 0.66 (0.57 to 0.74)
Continuation phase
0–1 drugs 66 56/487 7.6 3.3 to 11.9 0 (0 to 0.28)
2 drugs 140 438/8,884 3.8 2.5 to 5.1 0.54 (0.45 to 0.62)
3 or more drugs 72 307/4,824 4.5 2.4 to 6.5 0.54 (0.40 to 0.65)
Supervision of therapy
All doses fully supervised 225 693/9,323 7.3 5.8 to 8.8 0.48 (0.39 to 0.55)
None or partial DOT 76 237/6,235 2.4 1.6 to 3.2 0.43 (0.26 to 0.56)
Completion of therapy
Good (#10% dropouts) 175 640/10,340 5.5 4.1 to 6.8 0.56 (0.48 to 0.63)
Poor (.10% dropouts) 126 290/5,218 4.6 3.2 to 6.1 0.42 (0.29 to 0.53)
Event rate and 95% CI are in bold if confidence intervals for two or more strata do not overlap.
aIn all but one trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.
bIn a few trials the number of drugs was the same throughout—these were classified according to the starting regimen.
doi:10.1371/journal.pmed.1000146.t007
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settings.
The primary objective of this review was to compare the efficacy
of different durations and dosing schedule of rifampin. To
accomplish this, we have analyzed the per-protocol results from
each trial, using standardized microbiological definitions. All
studies reviewed reported adverse events, dropouts, and defaulters
separately, facilitating our approach. However, we did not include
these outcomes because they are not as well defined nor
standardized, potentially creating greater between-study variabil-
ity. As well, inter-study differences in providers and populations
could have very important influences on these outcomes—even
Table 8. Stratified estimates of acquired drug resistance in RCT in new cases.
Factor Arms (N) Events/Participants (N)
Pooled Event Rate
(Across All Trials) 95% CI I
2 (95% CI)
Overall
Rifampin use
a
Rifampin 1–2 mo 61 41/2,847 0.8 0 to 1.6 0 (0 to 0.28)
Rifampin 3–5 mo 33 10/1,932 0.3 0 to 0.6 0 (0 to 0.35)
Rifampin 6–7 mo 146 60/7,180 0.4 0.1 to 0.7 0 (0 to 0.19)
Rifampin 8+ mo 17 6/1,249 0.2 0 to 0.5 0 (0 to 0.46)
Use of intermittent therapy
a
Daily throughout 125 67/8,541 0.3 0.1 to 0.6 0 (0 to 0.20)
Daily then thrice weekly 28 3/636 0.6 0 to 1.8 0 (0 to 0.38)
Daily then twice weekly 36 12/1,748 0.4 0 to 1.0 0 (0 to 0.34)
Thrice weekly throughout 68 35/2,283 0.9 0 to 2.0 0 (0 to 0.28)
Initial drug resistance
Sensitive to all TB drugs 106 70/12,256 0.3 0.1 to 0.4 0 (0 to 0.22)
Isoniazid resistance 58 13/380 2.4 0.5 to 4.4 0 (0 to 0.29)
Streptomycin resistance 52 12/313 2.6 0.3 to 5.0 0 (0 to 0.32)
INH+streptomycin resistant (PDR) 41 22/259 5.7 1.3 to 10.1 0 (0 to 0.34)
Duration of pyrazinamide
No pyrazinamide 48 26/3,662 0.2 0 to 0.3 0 (0 to 0.30)
1–3 mo 113 46/5,536 0.5 0.1 to 0.9 0 (0 to 0.20)
4+ mo 96 45/4,010 0.5 0.1 to 1.0 0 (0 to 0.23)
Duration of streptomycin
No streptomycin 68 31/4,314 0.3 0 to 0.5 0 (0 to 0.24)
1–3 mo 101 51/5,585 0.4 0.1 to 0.7 0 (0 to 0.23)
4+ mo 88 35/3,309 0.8 0.1 to 1.6 0 (0 to 0.25)
Number of drugs to which strains susceptible
b
Initial phase
0–1 drugs 1 6/17 34.5 0 to 107.7 0 (–, –)
2 drugs 57 26/919 2.8 0.6 to 5.0 0 (0 to 0.29)
3 drugs 136 47/4,899 0.5 0.2 to 0.8 0 (0 to 0.20)
4 drugs 63 38/7,373 0.2 0 to 0.3 0 (0 to 0.28)
Continuation phase
0–1 drugs 62 26/511 2.8 0.4 to 5.3 0 (0 to 028)
2 drugs 126 65/8,037 0.4 0.1 to 0.6 0 (0 to 0.20)
3 or more drugs 63 26/4,634 0.2 0 to 0.4 0 (0 to 0.27)
Supervision of therapy
All doses fully supervised 200 101/8,364 0.7 0.3 to 1.2 0 (0 to 0.17)
None or partial DOT 57 16/4,844 0.1 0 to 0.3 0 (0 to 0.27)
Completion of therapy
Good (#10% dropouts) 148 71/9,483 0.3 0.1 to 0.5 0 (0 to 0.19)
Poor (.10% dropouts) 109 46/3,725 1.1 0.3 to 1.8 0 (0 to 0.22)
Event rate and 95% CI are in bold if confidence intervals for two or more strata do not overlap.
aIn all but one trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.
bIn a few trials the number of drugs was the same throughout—these were classified according to the starting regimen.
doi:10.1371/journal.pmed.1000146.t008
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would be balanced within each trial but could have created
substantial bias with our analytic approach. If dropout, default, or
side effects were associated with the same characteristics as failure
or relapse, then excluding these outcomes could underestimate the
poor outcomes associated with shorter rifampin exposures. But if
not, then including these outcomes would simply reduce all
differences between regimens.
Table 9. Adjusted incidence rate ratios of failure, relapse, and acquired drug resistance (from negative binomial regression).
Factor Failure IRR (95% CI) Relapse IRR (95% CI) Acquired Drug Resistance
a IRR (95% CI)
Duration of rifampin
b
1–2 mo 5.8 (2.9 to 11.0) 3.6 (2.5 to 5.3) 4.6 (2.0 to 0.4)
3–4 mo 1.3 (0.6 to 3.0) 2.6 (1.6 to 4.0) 1.2 (0.4 to 3.1)
5–7 mo 1.0 (reference) 1.0 (reference) 1.0 (reference)
8+ mo 2.0 (0.8 to 4.9) 0.4 (0.2 to 0.7) 2.1 (0.8 to 5.3)
Overall significance (p value)
c (,0.0001) (,0.0001) (,0.002)
Schedule of drug administration
b
Daily throughout 1.0 (reference) 1.0 (reference) 1.0 (reference)
Daily then thrice weekly 0.7 (0.2 to 2.1) 1.0 (0.6 to 1.5) 0.7 (0.2 to 2.6)
Daily then twice weekly 0.9 (0.5 to 1.6) 0.8 (0.5 to 1.2) 0.5 (0.3 to 1.2)
Thrice weekly throughout 0.7 (0.3 to 1.4) 1.2 (0.8 to 1.6) 2.4 (1.05 to 5.5)
Overall significance (p value)
c (0.66) (0.38) (0.02)
Other Factors
Initial drug resistance
d
DST not done/reported 3.3 (1.5 to 7.2) 3.0 (1.6 to 4.9) N/A
Pan-sensitive strain 1.0 (reference) 1.0 (reference) 1.0 (reference)
Isoniazid resistant 10.9 (5.9 to 20) 1.8 (1.2 to 2.6) 5.1 (2.3 to 11.0)
Streptomycin resistant 3.9 (1.4 to 11.0) 1.4 (0.9 to 2.2) 4.1 (1.6 to 10.0)
Poly-drug resistant (PDR) 33 (16 to 62) 1.8 (1.1 to 2.9) 10.0 (4.5 to 22.1)
Overall significance (p value)
c (,0.0001) (,0.0001) (,0.0001)
Use of pyrazinamide
b
Pyrazinamide not used 1.0 (reference) 1.0 (reference) 1.0 (reference)
Pyrazinamide used 4.7 (2.4 to 9.0) 0.7 (0.4 to 0.95) 2.4 (1.1 to 4.9)
Overall significance (p value)
c (,0.0001) (0.04) (0.02)
Use of streptomycin
b
Streptomycin not used 1.0 (reference) 1.0 (reference) 1.0 (reference)
Streptomycin used 0.3 (0.2 to 0.6) 0.9 (0.6 to 1.3) 0.7 (0.4 to 1.3)
Overall significance (p value)
c (0.0003) (0.67) (0.3)
Number of drugs to which strains susceptible*
Initial phase
0–1 drugs 99 (33 to 99) 1.6 (0.2 to 11.0) 74 (8.1 to 99)
2 drugs 20 (8.2 to 49) 1.1 (0.6 to 1.8) 6.7 (2.8 to 16)
3 drugs 2.6 (1.3 to 5.0) 1.1 (0.8 to 1.5) 2.9 (1.5 to 5.5)
4 or more drugs 1.0 (reference) 1.0 (reference) 1.0 (reference)
Overall significance (p value)
c (,0.0001) (0.9) (0.0004)
Continuation phase
0–1 drugs 1.1 (0.4 to 2.6) 1.2 (0.7 to 2.0) 2.9 (1.1 to 7.3)
2 drugs 0.5 (0.2 to 0.9) 0.8 (0.5 to 1.05) 1.7 (0.9 to 3.2)
3 or more drugs 1.0 (reference) 1.0 (reference) 1.0 (reference)
Overall significance (p value)
c (0.01) (0.08) (0.08)
aAcquired drug resistance in both failure and relapse cases combined.
bAdjusted estimates of Incidence Rate Ratios (IRR) from multivariate negative binomial regression with model that included all variables indicated, plus length of follow-
up after end of treatment (for relapse and acquired drug resistance), supervision of therapy (DOT), and non-completion of therapy because of protocol violations,
patient refusal, default, moved, or lost. Estimates that are statistically significant are in bold.
cOverall significance of each factor in multi-variate models, from log likelihood ratio test.
dAdjusted estimates of IRR from second model that included initial drug resistance, and all the same factors, but not the number of sensitive drugs in initial or
continuation phases. These could not be included because of substantial co-linearity with drug resistance.
doi:10.1371/journal.pmed.1000146.t009
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trials with direct head-to-head comparisons of rifampin duration,
and even fewer directly comparing intermittent regimens. Hence,
we had to pool results across studies; this increases potential
confounding from differences in treatment, patients’ disease
severity, or other differences in the study populations, since the
studies were conducted in many different countries. The
advantage of this approach is that we are able to include many
more trials, thereby increasing the precision and avoiding selection
bias [101]. However, the disadvantage is the greater potential for
bias due to between-trial differences in participant characteristics,
treatment regimens, as well as the differential impact of dropouts
and other losses to follow-up [102]. Concern about this latter
problem should be alleviated by the consistent results from three
analytic approaches—within the smaller set of trials with head-to-
head comparisons, across all 57 trials, and the multivariate
analysis. Also, the dispersion estimates from multivariable analysis
suggest that treatment factors and underlying drug resistance
accounted for almost all the differences in outcomes observed.
Most trials were initiated before 1980, limiting the number of
participants with HIV infection and drug resistance. The lack of
trials in HIV infected persons with active TB meant that the
question of rifampin duration in treatment of HIV-TB could not
be answered, due to insufficient power. This underscores the
paucity of recent TB treatment trials and the urgent need for trials
in drug resistant and/or HIV infected populations. There were no
trials in children, reflecting a lack of rigorous trials in this
population and the difficulties of microbiologic confirmation in
this population. Death was not analyzed, because most TB-related
deaths occur soon after diagnosis and are determined by
comorbidity, age, severity of illness, and delay in diagnosis
[103,104]. Deaths later in treatment are often from other causes
[105,106]. Hence, differences in the TB treatment regimen may
have relatively little impact on mortality. We endeavored to
minimize language bias by including studies published in French
and Spanish as well as English. Interestingly, this yielded only
three additional trials, or 5% of all trials included. In a recent
review [107], of all TB related papers listed in PubMed over 10 y,
papers published in English, French, and Spanish represented
84% of all published literature worldwide. Hence, this review can
be considered reasonably representative of publications in this
field. However, in some fields, such as mental health, PubMed will
fail to list a substantial proportion of relevant publications from
low- to middle-income countries [108], so we may have missed
some important trials.
Finally, we were not able to distinguish between relapse of the
same strain of M. tuberculosis that caused the initial infection and
reinfection with a new strain of the bacillus. In settings with high
rates of ongoing exposure to M. tuberculosis, particularly if HIV
seroprevalence is also high, a relatively high proportion of cases of
recurrent TB following initial apparent cure may be due to
reinfection [109]. However, very few participants had HIV
coinfection in the studies reviewed, and in studies with longer
follow-up, the great majority of relapses occurred in the first 1–2 y,
with very few occurring in the third to fifth years. This suggests
that reinfection should have accounted for very few of the disease
recurrences. Because follow-up was adequate in almost all
studies—only four studies had less than 1-y follow-up—unequal
follow-up should not have affected results—supported by the
finding that duration of post-treatment follow-up was not
associated with relapse rates in multivariable analysis.
Conclusion
This review provides evidence against continued use of
regimens that utilize rifampin for the first 2 mo only, as they
are significantly and substantially inferior to regimens that use
rifampin for at least 6 mo. This review also has identified an
important need for adequately powered clinical trials that
address dosing schedules, management of isoniazid mono-
resistance, and the optimal duration of treatment to prevent
relapse.
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Background. Tuberculosis—a contagious infection, usually
of the lungs—kills nearly two million people annually. It is
caused by Mycobacterium tuberculosis, bacteria that are
spread in airborne droplets when people with tuberculosis
cough. Most people infected with M. tuberculosis do not
become ill—their immune system contains the infection.
However, the bacteria remain dormant within the body and
can cause tuberculosis years later if immunity declines
because of, for example, infection with HIV (the virus that
causes AIDS). The symptoms of tuberculosis include a
persistent cough, weight loss and night sweats. The
disease can usually be cured by taking several powerful
antibiotics regularly for several months although drug-
resistant tuberculosis is increasingly widespread. The
standardized drug regimen recommended by the World
Health Organization (WHO) for previously uninfected
patients consists of an initial treatment phase, in which
rifampin, isoniazid, ethambutol, and pyrazinamide are taken
daily or thrice weekly for 2 months, and a continuation
phase, in which two antibiotics are taken for a further 4–6
months.
Why Was This Study Done? Resistance to rifampicin,
which can develop if this drug is not taken regularly, is
associated with poor treatment outcomes, particularly in
patients infected with isoniazid-resistant M. tuberculosis.
WHO recommends, therefore, that health-care workers
watch patients take all their doses of rifampicin (‘‘directly
observed therapy’’). Treatment regimens for tuberculosis
that use rifampicin only during the initial phase and/or give
rifampicin several times a week (intermittently) rather than
daily would make direct observation of treatment much
easier but are such regimens effective? In this study (which,
together with two similar studies, was commissioned by
WHO to provide the evidence needed for a revision of their
treatment guidelines), the researchers undertook a
systematic review (a search using specific criteria to
identify relevant research studies, which are then appraised
and analyzed according to an explicit protocol) and a meta-
analysis (a statistical approach that pools the results of
several studies) of published trials of various rifampicin-
containing regimens for the treatment of tuberculosis in
previously untreated patients.
What Did the Researchers Do and Find? The researchers
identified 57 randomized controlled trials (studies in which
groups of patients are randomly assigned to different
interventions) that reported the treatment failure and/or
relapse rates (determined by seeing whether M. tuberculosis
could be grown from sputum brought up from the lungs by
coughing, so-called bacteriologically confirmed tuberculosis)
associated with various rifampicin-containing treatment
regimens. In their statistical analysis of the results of these
trials (which involved more than 21,000 previously untreated
patients), the researchers found that regimens that used
rifampicin during only the first 1–2 months of treatment had
higher rates of failure, relapse, and acquired drug resistance
than regimens that used rifampicin for 6 months. Indeed,
relapse rates decreased with the duration of rifampicin
treatment up to 8 months of treatment. Furthermore,
outcomes were particularly bad with regimens that
included rifampicin during only the first 1–2 months of
treatment if there was initial resistance to isoniazid and/or
streptomycin (another antibiotic). Outcomes were similar,
however, in regimens in which rifampicin was given daily
throughout treatment, daily during the initial phase then
twice or thrice weekly, or thrice weekly throughout
treatment; insufficient evidence was available to evaluate
the efficacy of regimens in which rifampicin was given twice
weekly throughout treatment.
What Do These Findings Mean? These findings suggest
that tuberculosis treatment regimens for previously
untreated patients who use rifampicin during only the first
two months of treatment should be phased out and
replaced by regimens that use rifampicin for 6 months,
particularly in settings where there is likely to be resistance
to isoniazid and/or streptomycin. This recommendation will
be made in the planned 2009 revision of the WHO
tuberculosis treatment guidelines. In addition, these
findings suggest that giving rifampicin thrice weekly is as
effective as giving it daily during the initial phase or
throughout treatment. Importantly, these findings also
indicate that more trials are needed to investigate other
dosing schedules, to determine the optimal duration of
treatment, and to determine the best way to manage
patients infected with isoniazid-resistant bacteria. Finally,
since very few of the trials identified in the systematic review
included HIV-positive participants, trials designed to test
drug regimens in people infected with both HIV and M.
tuberculosis are urgently needed to reduce global deaths
from tuberculosis.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000146.
N The results of another WHO-commissioned study into the
treatment of tuberculosis are presented in a separate PLoS
Medicine Research Article by Menzies et al. (Menzies D,
Benedetti A, Paydar A, Royce S, Pai M, et al. (2009)
Standardized Treatment of Active Tuberculosis in Patients
with Previous Treatment and/or with Mono-resistance to
Isoniazid: A Systematic Review and Meta-analysis. PLoS
Med 6(9): e1000150. doi:10.1371/journal.pmed.1000150)
N The US National Institute of Allergy and Infectious Diseases
provides information on all aspects of tuberculosis
N The US Centers for Disease Control and Prevention provide
several facts sheets and other information resources about
tuberculosis
N The American Thoracic Society, US Centers for Disease
Control and Prevention, and Infectious Diseases Society of
America have published guidelines on TB treatment
N The 2003 (2004 revision) WHO guidelines for national
programs for the treatment of tuberculosis are available;
WHO also provides information on efforts to reduce the
global burden of tuberculosis (in several languages) and its
2009 annual report on global control of tuberculosis
describes the current situation (key points are available in
several languages)
N The WHO publishes guidelines on TB treatment
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